<unk>  is a monoclonal antibody that is FDA approved for the treatment of non–hodgkin's lymphoma (nhl), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) (wegener's granulomatosis) and microscopic polyangiitis (MPA),. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hypotension, peripheral edema, night sweats, pruritus, rash, abdominal pain, diarrhea, nausea, vomiting, anemia, arthralgia, backache, myalgia, asthenia, dizziness, headache, sensory neuropathy, increasing frequency of cough, rhinitis, fever, infectious disease, pain, shivering.
Rituximab
Bavituximab
Lenalidomide
Alemtuzumab
Ruxolitinib
Ibrutinib
Adalimumab
Interferon alfa-2a